Our Pipeline
Xyngari (formerly DMT310)
Xyngari is our lead product candidate, developed from our Spongilla platform technology that is currently in Phase 3 clinical trials for the treatment of acne. The unique product candidate is derived from a natural source of Spongilla lacustris, which contains multiple active components to treat a variety of inflammatory skin diseases with once weekly applications. It is currently under development for the treatment of moderate to severe acne, mild to moderate psoriasis, and moderate to severe papulopustular rosacea. It contains a unique freshwater sponge that is harvested from a select region of the world, under specific environmental conditions to ensure the sponge retains its distinctive anti-inflammatory, anti-microbial and mechanical properties. After processing, the sponge powder contains precisely sized and shaped silica spicules that upon application may help exfoliate the skin, promote collagen production, open closed comedones (creating an aerobic environment to help kill C. acne bacteria) and create microchannels to facilitate penetration of the sponge’s naturally occurring chemical compounds. These chemical compounds have been shown, in-vitro, to have both antimicrobial and anti-inflammatory properties, which we believe play a significant role in the treatment of inflammatory skin diseases, such as acne. We believe the combination of the spicules and the unique chemical compounds within the sponge may lead to a topical product that only needs to be applied once per week and we believe may have a faster time to treatment effect than currently available products.
DMT400
DMT400 is a combination regimen using our unique Spongilla technology facilitate the dermal delivery of macro-molecules that typically must be injected. The sponge’s microscopic needle-like spicules penetrate through the stratum corneum, creating micro channels in the skin, allowing a topically applied macro-molecule to be massaged onto the skin and penetrate into the dermis. DMT400’s combination regimen produces many potential benefits over the use of injections, including the potential for lower systemic exposure allowing for the use of biologics in a milder patient population, more targeted delivery of the macro-molecule to the areas of the skin with lesions/disease and greater patient acceptance due to the injection-free delivery. We believe the DMT400 regimen has the potential to be used for the topical delivery of biologic molecules for numerous skin diseases and cosmetic applications, such as hyperhidrosis, psoriasis, acne, rosacea and other aesthetic indications.
DMT410
DMT410 is our second development program using our DMT400 combination regimen in combination with botulinum toxin. We have completed a proof of concept, Phase 1 clinical trial using DMT410 in combination with BOTOX® for the treatment of primary axillary hyperhidrosis. In this study, 10 patients received application of our sponge powder to each axillae, which after being washed off, was followed by a topical application of BOTOX® to each axillae. The treatment was well tolerated, and a majority of patients saw a reduction in sweat production similar to results seen from using interdermal injections of BOTOX®. We also conducted a Phase 1 proof of concept trial of DMT410 in combination with BOTOX® for the treatment of multiple aesthetic skins conditions. This study enrolled 10 patients who each received one application of reconstituted DMT310 followed by one topical application of BOTOX® to the upper face. Many patients saw clinical improvement in multiple aesthetic skin conditions measured in the study, including a reduction in pore size, fine lines, and sebum production and an improvement in luminosity and brightness as well as a improvement in their global aesthetic score. We are currently seeking a botulinum toxin partner to conduct further clinical studies with DMT410.
